News and Congratulations
Congratulations to CTSC KL2 Scholar and Master's degree alumni, Dr. Scott Tagawa, MD, MS, FACP, FASCO, on discussing the evolving treatment model in advanced urothelial carcinoma during a session at the Bladder Cancer Advocacy Network (BCAN) 2023 Think Tank.
Dr. Tagawa was appointed a KL2 Scholar in 2008 and received his Master's degree in 2010 where his research focused on "Anti-PSMA Based Radioimmunotherapy for Prostate Cancer". During his KL2 and Master's training, Dr. Tagawa's mentoring team included Dr. David Nanus, MD of Weill Cornell Medicine and Dr. Neil Bander, MD of Weill Cornell Medicine.
As the Medical Director of the Genitourinary Oncology Research Program, Dr. Tagawa leads clinical trials in the areas of prostate, kidney, and bladder cancer as well as the prevention and treatment of thrombosis with cancer. He specializes in drug development and theranostics in prostate cancer. Dr. Tagawa also serves as Associate Director of Clinical Research for the Division of Hematology and Medical Oncology, Medical Director of the Cancer Clinical Trials Office of the Meyer Cancer Center, and Chair of the Feasibility Committee for cancer clinical research.
The Master's Degree in Clinical Translational Investigation combines rigorous academics and strategic, practical skills, challenging students to apply scientific theory, concepts, methods, and innovative, team-oriented management to help solve complex biomedical and health issues.
The CTSC KL2 Career Development Core Program supports junior faculty and senior residents and fellows by providing salary support, protected time, advanced degree training, and practical skills necessary to conduct interdisciplinary Clinical Translational Investigation within a team research environment.